These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 17010473)

  • 1. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs.
    Sakagami M
    Adv Drug Deliv Rev; 2020; 161-162():63-74. PubMed ID: 32763274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo animal models for drug delivery across the lung mucosal barrier.
    Cryan SA; Sivadas N; Garcia-Contreras L
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1133-51. PubMed ID: 17900750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of models for the evaluation of pulmonary drug disposition.
    Liu X; Jin L; Upham JW; Roberts MS
    Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):487-505. PubMed ID: 23294005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human respiratory epithelial cell culture for drug delivery applications.
    Forbes B; Ehrhardt C
    Eur J Pharm Biopharm; 2005 Jul; 60(2):193-205. PubMed ID: 15939233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
    Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
    Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary drug delivery: physiologic and mechanistic aspects.
    Yu J; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1997; 14(4):395-453. PubMed ID: 9450176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical models for pulmonary drug delivery.
    Fernandes CA; Vanbever R
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1231-45. PubMed ID: 19852680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical perspectives on pulmonary systemic and macromolecular delivery.
    Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity.
    Madlova M; Bosquillon C; Asker D; Dolezal P; Forbes B
    J Pharm Pharmacol; 2009 Mar; 61(3):293-301. PubMed ID: 19222901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The particle has landed--characterizing the fate of inhaled pharmaceuticals.
    Patton JS; Brain JD; Davies LA; Fiegel J; Gumbleton M; Kim KJ; Sakagami M; Vanbever R; Ehrhardt C
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S71-87. PubMed ID: 21133802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models.
    Godin B; Touitou E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1152-61. PubMed ID: 17889400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating systemic diseases via the lung.
    Sanjar S; Matthews J
    J Aerosol Med; 2001; 14 Suppl 1():S51-8. PubMed ID: 11424894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols.
    Byron PR; Hindle M; Lange CF; Longest PW; McRobbie D; Oldham MJ; Olsson B; Thiel CG; Wachtel H; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S59-69. PubMed ID: 21133801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition.
    Pang Y; Sakagami M; Byron PR
    Eur J Pharm Sci; 2005; 25(4-5):369-78. PubMed ID: 15979534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model.
    Beck-Broichsitter M; Gauss J; Packhaeuser CB; Lahnstein K; Schmehl T; Seeger W; Kissel T; Gessler T
    Int J Pharm; 2009 Feb; 367(1-2):169-78. PubMed ID: 18848609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary drug delivery: medicines for inhalation.
    Henning A; Hein S; Schneider M; Bur M; Lehr CM
    Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation.
    Ong HX; Benaouda F; Traini D; Cipolla D; Gonda I; Bebawy M; Forbes B; Young PM
    Eur J Pharm Biopharm; 2014 Jan; 86(1):83-9. PubMed ID: 23851077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.